Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Navidea Biopharmaceuticals Inc    NAVB

 SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
02/13/2017 02/14/2017 02/15/2017 02/16/2017 02/17/2017 Date
0.4319(c) 0.4225(c) 0.4378(c) 0.4399(c) 0.4452(c) Last
2 691 975 996 833 589 318 323 220 359 132 Volume
+25.66% -2.18% +3.62% +0.48% +1.20% Change
More quotes
Financials ($)
More Financials
Company
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutic.It is developing multiple precision-targeted products based on their manocept platform to help identify the sites and... 
More about the company
Latest news on NAVIDEA BIOPHARMACEUTICALS
02/17 NAVIDEA BIOPHARMACEUTICALS, INC. (NY : NAVB) Files An 8-K Other Events
02/16 NAVIDEA BIOPHARMACEUTICALS, INC. : Other Events (form 8-K)
02/10 NAVIDEA BIOPHARMACEUTICALS, INC. : Change in Directors or Principal Officers (fo..
01/27 NAVIDEA BIOPHARMACEUTICALS : to Hold Conference Call to Provide Investor Update ..
01/25 NAVIDEA BIOPHARMACEUTICALS : Research Reports Coverage on Biotech Stocks -- Phar..
01/06 NAVIDEA BIOPHARMACEUTICALS : to Present at Upcoming Investor Conference
2016 NAVIDEA BIOPHARMACEUTICALS : Signs Asset Purchase Agreement with Cardinal Health
2016 NAVIDEA BIOPHARMACEUTICALS, INC. (NY : NAVB) Files An 8-K Entry into a Material ..
2016 NAVIDEA BIOPHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, F..
2016 NAVIDEA BIOPHARMACEUTICALS : Signs Asset Purchase Agreement with Cardinal Health
More news
Sector news : Biotechnology & Medical Research - NEC
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
02/13 TEVA PHARMACEUTICAL INDUSTRIES : seeks CEO with pharma background to lead recove..
02/08DJAppeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol Drug
02/08 Weak pound buoys GSK but drugmaker warns on 2017 generic threat
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2016 Navidea sells Lymphoseek to Cardinal Health for up to $310M; shares up 5%
2016 Trading in Navidea halted pending news
2016 Navidea Biopharmaceuticals' (NAVB) CEO Michael Goldberg on Q3 2016 Results - ..
2016 Navidea Biopharm net loss improves in Q3
2016 Navidea Biopharm beats by $0.02, beats on revenue
Advertisement
Chart NAVIDEA BIOPHARMACEUTICALS
Duration : Period :
Navidea Biopharmaceuticals Technical Analysis Chart | NAVB | US63937X1037 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target -100%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mike M. Goldberg President, Chief Executive Officer & Director
Jed Andrew Latkin Chief Operating & Financial Officer
Frederick O. Cope Chief Scientific Officer & Senior Vice President
Michael Tomblyn Chief Medical Officer & Senior Vice President
David Colborn Vice President-Clinical Operations
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NAVIDEA BIOPHARMACEUTI..-31.00%69
INCYTE CORPORATION20.17%22 822
QUINTILES IMS HOLDINGS..0.92%18 894
CELLTRION, INC.--.--%10 747
LONZA GROUP AG1.87%10 368
SEATTLE GENETICS, INC.24.12%9 272
More Results